Pharming Group company profile

PHARM · Euronext Amsterdam · EUR

Compare Pharming Group
€1.08Change from previous close: −3.05%Absolute change: −€0.03

Close · November 20, 2026

Company profile

Pharming Group has 407 employees and is headquartered in Leiden, Netherlands.

Pharming Group N.V. develops and commercializes protein replacement therapies and precision medicines for rare diseases, with commercial activity in the United States, Europe and other markets worldwide. Its lead product is RUCONEST, a treatment for acute attacks of hereditary angioedema in adults and adolescents. Joenja, an oral medicine for activated phosphoinositide 3-kinase delta syndrome, is the other principal product, and the company continues to develop it alongside a partnership with Novartis.

In the fiscal year ended December 2025, revenue reached USD 376.1 million, up 26.6% on the previous year, while net profit stood at USD 2.9 million. The company had 407 employees and is headquartered in Leiden, the Netherlands, where it was incorporated in 1988.

Company facts

Industry
Biotechnology
Headquarters
Darwinweg 24, 2333 CR, Leiden
Employees
407
Chief executive
Fabrice Chouraqui
Founded
1988
Fiscal year
January - December
Listing
PHARM · Euronext Amsterdam
Currency
EUR
ISIN
NL0010391025

Pharming Group and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
Pharming GroupPHARMNetherlands$841.25M40712.8%36.1
InventivaIVAFrance$890.8M87-5,980.9%—
PhilogenPHILItaly$905.96M23079.1%3.67
Basilea PharmaceuticaBSLNSwitzerland$1.07B20024.2%18.1
GubraGUBRADenmark$730.02M330-73.1%—
Pharma MarPHMSpain$1.1B50521.3%14.7

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Pharming Group with its competitors